explore -WSS

explore

author：entertainment 2025-09-06 03:28:20 - browse：66949

BRENDAN SMIALOWSKI/AFP via Getty Images

A New York jury on Wednesday convicted the former CEO of Stimwave, a company that sold devices with dummy pieces of plastic, on two counts of health care fraud. The maximum jail sentence for each count is 20 years.

Laura Perryman led Stimwave, which sold nerve stimulation devices to combat pain, from 2010 to 2019. Under her leadership, Stimwave distorted the design of the device to better fit insurance codes, resulting in unnecessary plastic components that allowed the company to sell its products for thousands of dollars more than it otherwise could. From 2017 to 2020, the company sold nearly 8,000 devices with the non-functioning component.

STAT published new details about the Stimwave story last May, after former employees described how Perryman broke into Stimwave’s Florida headquarters to steal back devices after her termination in 2019. The fraud laid bare the limits of the Food and Drug Administration’s device surveillance system, doctors’ ability to scrutinize device effectiveness, and how impossible it is for patients to get answers about the implants they receive.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Psychedelics group wrestles with new pharma identity

focus

WSS

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth quietly bought dozens of outpatient centers

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

State Dept. review finds Biden bears some blame for Afghanistan failures

How to bring more disabled researchers into academia

In Memoriam: Notable people who died in 2023

entertainment

explore

leisure time

Supreme Court strikes down use of affirmative action

Wildfire smoke exposes gaps in outdoor worker protections

Duchenne breakthrough therapy leaves behind pioneering families

Sen. Paul opposes bill to ban Chinese biotechs

BioMarin wins approval for gene therapy to treat hemophilia A

First medicine developed to treat MASH expected to be approved soon

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

In age of alternative facts, a scholarly course on calling out crap

Duchenne breakthrough therapy leaves behind pioneering families

Sen. Paul opposes bill to ban Chinese biotechs

entertainment

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

NEJM study link tiny plastics in blood vessels to heart problems

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

The high cost of giving birth even with insurance

Change Healthcare payments predicted restored March 15

First medicine developed to treat MASH expected to be approved soon

focus

explore

focus

Wikipedia